1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
EirGenix, Inc.

EirGenix, Inc.

TTWSE:6589
49.70
TWD
+0.35
(+0.71%)
-1.88EPS
14.90BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.2
0.92
1.19
2.39
2.68
2.12
2.84
5.3
6.99
4.88
3.35
3.3
3.32
4.02
Basic EPS, GAAP
-2.5
-2.26
-1.55
-1.06
-1.57
-2.76
-5.13
-5.15
-0.18
-0.38
-3
-2.28
-2.51
-1.88
Free Cash Flow per Basic Share
-6.08
-3.08
-2.29
-1.28
-4.94
-10.88
-7.12
-2.29
-0.82
-3.09
-5.17
-4.05
-4.38
-1.35
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.15
9.42
8.22
11.67
10.2
12.99
10.16
8.79
34.72
35.1
32.73
30.31
27.57
26.09
Tangible Book Value per Share
3.98
8.38
7.3
11.02
9.66
12.65
9.93
8.63
34.65
35.01
32.64
30.25
26.12
24.52
Basic Weighted Avg Shares
42
59
87
106
111
133
168
202
243
303
305
306
302
302
Sales/Revenue/Turnover
9
54
103
253
298
282
476
1,072
1,697
1,481
1,023
1,009
1,005
1,213
Operating Margin (%)
-1,231.74
-287.84
-153.91
-54.46
-58.77
-133.4
-178.05
-91.99
-3.39
-22.36
-100.91
-85.82
-83.9
-73.37
Depreciation Expense
8
25
28
31
38
42
114
172
185
205
239
302
246
260
Net Income, GAAP
-105
-133
-135
-112
-175
-368
-861
-1,042
-43
-116
-915
-698
-761
-569
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,221.73
-247.06
-130.93
-44.41
-58.7
-130.32
-180.83
-97.19
-2.51
-7.8
-89.49
-69.21
-75.67
-46.89
Working Capital
245
542
450
985
483
951
568
852
8,367
7,557
6,208
5,005
3,327
2,768
LT Debt
- -
- -
- -
- -
208
600
966
1,223
288
432
437
668
1,384
1,679
Total Equity
442
809
706
1,306
1,145
2,088
1,855
1,906
10,429
10,683
10,017
9,258
8,342
7,792
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-21.26
-17.77
-11.18
-14.27
-22.76
-43.67
-55.4
-0.69
-1.09
-8.84
-7.25
-8.64
-7

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
322
22
83
LT Borrowings
883
1,002
1,181
LT Finance Leases
501
496
498
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
303
303
299
Market Capitalization
18,670
16,597
14,903

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,544
4,188
3,895
Cash, Cash Equivalents & STI
3,526
3,258
2,859
Accounts Receivable, Net
114
43
66
Inventories
493
522
606
Total Current Liabilities
1,217
911
1,127
Payables & Accruals
- -
- -
- -
ST Debt
322
22
83
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.27%
85.2%
-9.9%
Free Cash Flow
72.38%
73.2%
6.84%
Net Income, GAAP
105.72%
150.55%
8.91%
Sales/Revenue/Turnover
36.55%
2.59%
-0.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
220
246
248
295
1,009
2025
182
231
229
364
1,005
2026
308
312
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.34
-0.72
-0.84
-0.39
-2.28
2025
-0.52
-1.23
-0.2
-0.57
-2.51
2026
-0.47
-0.64
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li Cheng Liu
Full Time Employees
1,000
Sector
Health technology
Industry
Biotechnology
Address
No. 101, Kangning Street New Taipei TP Taiwan 22180
IPO Date
Nov 23, 2016
Website
eirgenix.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
EirGenix Inc. (Ticker: 6589.TWO) is a biotechnology company primarily engaged in the development, manufacturing, and commercialization of therapeutic antibodies and biologics aimed at treating cancer and autoimmune diseases. Its core product offerings include recombinant antibody drugs, immunotherapy agents, biopharmaceuticals, and related diagnostic tools. EirGenix focuses on cutting-edge antibody engineering technologies and bioprocessing to develop innovative treatments that address unmet medical needs. The company operates mainly in Taiwan and has a growing presence in international markets. Founded in 2005 and headquartered in Taipei, Taiwan, EirGenix has recently undertaken significant strategic initiatives to expand its product pipeline and global reach. In the past two years, the company has entered into key partnerships to advance its immuno-oncology portfolio and has made substantial progress in proprietary monoclonal antibody development. Additionally, EirGenix has launched new biologic candidates targeting specific cancer types and autoimmune conditions, reflecting a strategic shift toward precision medicine. The company also completed a notable funding round to support R&D and global commercialization efforts, enhancing its operational scale and technological capabilities. EirGenix serves pharmaceutical companies, healthcare providers, and research institutions across Asia and increasingly in Western markets, positioning itself within the broader biotechnology and pharmaceutical industries. Its business segments include antibody therapeutics development, contract manufacturing services, and biologics research collaborations. Operating subsidiaries and alliances complement its capabilities, reinforcing its commitment to innovative life sciences solutions. This comprehensive company profile underscores EirGenix Inc.’s role as a specialized biopharmaceutical entity focused on delivering advanced antibody-based therapies, supported by strategic growth actions and geographical expansion in the dynamic healthcare sector.